Therapy of Type 2 Diabetes Mellitus

  • Zachary Bloomgarden


Given the relationship between glycemia and the complications of diabetes, a number of recommendations have been put forward regarding the goals of glycemic control for patients with diabetes. The most commonly cited are those of the American Diabetes Association, which has given three ascending sets of levels, those to be considered “normal,” those to be used as the “goal” for patients with diabetes, and those above which additional measures are clearly thought to be recommended (Table 1).


Beta Cell Glycemic Control Behavioral Risk Factor Surveillance System Insulin Lispro Gastric Inhibitory Polypeptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Diabetes Association Position Statement. Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care 24 (Suppl 1), 2001. Downloaded September 15, 2001 from http://www. Scholar
  2. 2.
    AACE Consensus Conference on Guidelines for Glycemic Control. Endocrine Practice Nov/Dec 2001. Downloaded September 15, 2001 from whitepaper.php.Google Scholar
  3. 3.
    Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22: 403–8, 1999.PubMedGoogle Scholar
  4. 4.
    State-specific prevalence of participation in physical activity Behavioral Risk Factor Surveillance System, 1994. MMWR Morb Mortal Wkly Rep 45: 673–675, 1996.Google Scholar
  5. 5.
    Spelsberg A, Manson JE. Physical activity in the treatment and prevention of diabetes. Compr Ther 21: 559–562, 1995.PubMedGoogle Scholar
  6. 6.
    Prevalence of physical inactivity during leisure time among overweight persons-Behavioral Risk Factor Surveillance System, 1994. MMWR Morb Mortal Wkly Rep 45: 185–188, 1996.Google Scholar
  7. 7.
    Monterrosa AE, Haffner SM, Stern MP, Hazuda HP. Sex difference in lifestyle factors predictive of diabetes in Mexican-Americans. Diabetes Care 18: 448–4, 1995.PubMedGoogle Scholar
  8. 8.
    Knuiman MW, Welborn TA, Bartholomew HC. Self-reported health and use of health services: a comparison of diabetic and nondiabetic persons from a national sample. Aust NZ J Public Health 20: 241–247, 1996.Google Scholar
  9. 9.
    Tessier D, Menard J, Fulop T, Ardilouze J, Roy M, Dubuc N, Dubois M, Gauthier P. Effects of aerobic physical exercise in the elderly with type 2 diabetes mellitus. Arch Gerontol Geriatr 31: 121–132, 2000.PubMedGoogle Scholar
  10. 10.
    Ravussin E, Valencia ME, Esparza J, Bennett PH, Schulz LO. Effects of a traditional lifestyle on obesity in Pima Indians. Diabetes Care 17: 1067–1074, 1994.PubMedGoogle Scholar
  11. 11.
    Chaturvedi N, Stephenson JM, Fuller JH. The relationship between socioeconomic status and diabetes control and complications in the EURODIAB IDDM Complications Study. Diabetes Care 19: 423–430, 1996.PubMedGoogle Scholar
  12. 12.
    Murphy E, Kinmonth AL. No symptoms, no problem? Patients’ understandings of non-insulin dependent diabetes. Fam Pract 12: 184192, 1995.Google Scholar
  13. 13.
    Connolly VM, Kesson CM. Socioeconomic status and clustering of cardiovascular disease risk factors in diabetic patients. Diabetes Care 19: 419–422, 1996.PubMedGoogle Scholar
  14. 14.
    Harris LE, Luft FC, Rudy DW, Tierney WM. Correlates of health care satisfaction in inner-city patients with hypertension and chronic renal insufficiency. Soc Sci Med 41: 1639–1645, 1995.PubMedGoogle Scholar
  15. 15.
    Garay-Sevilla ME, Nava LE, Malacara JM, et al. Adherence to treatment and social support in patients with non-insulin dependent diabetes mellitus. J Diab Compi 9: 81–86, 1995.Google Scholar
  16. 16.
    Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, Carney RM, McGill JB. Effects of alprazolam on glucose regulation in diabetes: results of a double-blind, placebo-controlled trial. Diabetes Care 18: 1133–1139, 1995.PubMedGoogle Scholar
  17. 17.
    Bailey, CJ. The Diabetes Prevention Program: headline results. Br J Diabetes Vase Dis 1: 62–64, 2001.Google Scholar
  18. 18.
    Tuomilehto J, Lindstorm JH, Erikson JG for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. NEngl J Med 333: 1343–50, 2001.Google Scholar
  19. 19.
    Pan X, Li G, Hu Y, Wang J, Yang With, An Z. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Ga Qing IGT and diabetes study. Diabetes Care 20: 537–44, 1997.PubMedGoogle Scholar
  20. 20.
    Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268: 423–426, 1995.PubMedGoogle Scholar
  21. 21.
    Bloomgarden, ZT., Perspectives on the News: International Diabetes Federation Meeting, 1997: Issues in the treatment of type 2 diabetes: Sulfonylureas, metformin, and troglitazone. Diabetes Care 21: 1024–1026, 1998.PubMedGoogle Scholar
  22. 22.
    Barzilai N, Groop PH, Groop L, DeFronzo RA. A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. Acta Diabetol 32: 273–278, 1995.PubMedGoogle Scholar
  23. 23.
    Levy J, Vandenberg M, Grunberger G. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus: effects on blood pressure and glucose tolerance. Am J Hypertens 8: 445–453, 1995.PubMedGoogle Scholar
  24. 24.
    Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 28: 115–137, 1995.Google Scholar
  25. 25.
    Leibowitz G, Cerasi E. Sulfonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 39: 503–514, 1996.PubMedGoogle Scholar
  26. 26.
    UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998.Google Scholar
  27. 27.
    Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118: 169–172, 1993.PubMedGoogle Scholar
  28. 28.
    Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate release glipizide in patients with NIDDM. Diabetes Care 17: 1460–1464, 1994.PubMedGoogle Scholar
  29. 29.
    Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette C, The Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Diabetes Care 20: 597–606, 1997.PubMedGoogle Scholar
  30. 30.
    Peters AL, Davidson MB. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab 81: 2423–2437, 1996.PubMedGoogle Scholar
  31. 31.
    Banerji MA, Chaiken RL, Lebovitz HE. Prolongation of nearnormoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes 44: 466–470, 1995.PubMedGoogle Scholar
  32. 32.
    Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 44: 751–755, 1996.PubMedGoogle Scholar
  33. 33.
    Bokvist K, Hoy M, Buschard K, Holst JJ, Thomsen MK, Gromada J. Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic beta cells. Eur J Pharmacol 386: 105–11, 1999.PubMedGoogle Scholar
  34. 34.
    Hu S, Wang S, Dunning BE. Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta cell K(ATP) channels. J Pharmacol Exp Ther 291: 1372–9, 1999.PubMedGoogle Scholar
  35. 35.
    Norman P, Rabasseda X. Nateglinide: a structurally novel insulin secretion agent. Drugs of Today 37 (Suppl F): 1–16, 2001.Google Scholar
  36. 36.
    Package insert, Prandin (repaglinide). NovoNordiskGoogle Scholar
  37. 37.
    Bloomgarden, ZT. Metformin. Diabetes Care 18: 1078–1080, 1995.Google Scholar
  38. 38.
    Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 17: 1100–1109, 1994.PubMedGoogle Scholar
  39. 39.
    UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 43). Lancet 352: 854–865, 1998.Google Scholar
  40. 40.
    DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. N Engl J Med 333: 541–549, 1995.PubMedGoogle Scholar
  41. 41.
    Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IR One year comparative: trial of metformin and glipizide in type II diabetes mellitus. Diab Metab 20: 394–400, 1994.Google Scholar
  42. 42.
    Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Medication 103: 491–7, 1997.Google Scholar
  43. 43.
    Hermann LS, Schersten B, Melander A. Antihyperglycemic efficacy, response prediction and dose-responsee relationships of treatment with metformin and sulphonylureas, alone and in primary combination. Diabet Med 11: 953–60, 1994.PubMedGoogle Scholar
  44. 44.
    McIntyre HD, Ma A, Bird DM, Paterson CA, Ravenscroft PJ, Cameron DP. Metformin increases insulin sensitivity and basal glucose clearance in type 2 diabetes. Aust NZ J Medication 21: 714–9, 1991.Google Scholar
  45. 45.
    Grant PJ. The effects of high-and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 19: 64–66, 1996.PubMedGoogle Scholar
  46. 46.
    Glucophage (metformin) package insert. Bristol-Myers Squibb Company. October 1997.Google Scholar
  47. 47.
    Campbell IW. Metformin and the sulfonylureas: the comparative risk. Horm Metab Res Suppl. 15: 105–111, 1985.PubMedGoogle Scholar
  48. 48.
    Acarbose for diabetes mellitus. Med Lett Drugs Ther 38 (967): 9–10, 1996.Google Scholar
  49. 49.
    Hoffmann J, et al. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: the Essen Study. Diabetes Care 17: 561–566, 1994.PubMedGoogle Scholar
  50. 50.
    Pagano G, Marena S, Corgiat-Mansin L, et al. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diab Metab 21: 162–167, 1995.Google Scholar
  51. 51.
    Rodger NW, Chiasson JL, Josse RG, et al. Clinical experience with acarbose: results of a Canadian multicentre study. Clin Invest Med 18: 318–324, 1995.PubMedGoogle Scholar
  52. 52.
    Coniff RF, Shapiro JA, Robbins D, Kleinfeld R, Seaton TB, Beisswenger P, McGill JB. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care 18: 817–824, 1995.PubMedGoogle Scholar
  53. 53.
    Rosak C, Nitzsche G, Konig P, Hofman U. The effect of timing and the administration of acarbose on postprandial hyperglycemia. Diabet Med 12: 979–984, 1995.PubMedGoogle Scholar
  54. 54.
    Josse RG. Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. Diabetes Res Clin Pract 28: 167–172, 1995.Google Scholar
  55. 55.
    Johnston PS, Coniff RF, Hoogwerf BJ, et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 17: 20–29, 1994.PubMedGoogle Scholar
  56. 56.
    Vannasaeng S, Ploybutr S, Nitiyanant W, et al. Effects of alphaglucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus. J Med Assoc Thai 78: 578–585, 1995.PubMedGoogle Scholar
  57. 57.
    Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA. A double blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 18: 928–932, 1995.PubMedGoogle Scholar
  58. 58.
    Calle-Pascual AL, Garcia-Honduvilla J, Martin-Alvarez PJ, Vara E, Calle JR, Munguira ME, Maranes JP. Comparison between acarbose, metformin, and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diab Metab 21: 256–260, 1995.Google Scholar
  59. 59.
    Bayraktar M, Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 19: 252–254, 1996.PubMedGoogle Scholar
  60. 60.
    Bloomgarden, ZT., Perspectives on the News: European Association for the Study of Diabetes Meeting, 1998: Treatment of type 2 diabetes and the pathogenesis of complications. Diabetes Care 22: 1209–1215, 1999.PubMedGoogle Scholar
  61. 61.
    Petrie J, Small M, Connell J. Glitazones, a prospect for non-insulindependent diabetes. Lancet 349: 370–371, 1997.Google Scholar
  62. 62.
    Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee Cox L, Smith SA. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 284: 751–9, 1998.PubMedGoogle Scholar
  63. 63.
    Whitcomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs 4: 1299–1309, 1995.Google Scholar
  64. 64.
    Kuehnle HF. New therapeutic agents for the treatment of NIDDM. Exp Clin Endocrinol Diabetes 104: 93–101, 1996.PubMedGoogle Scholar
  65. 65.
    Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8: 316–320, 1995.PubMedGoogle Scholar
  66. 66.
    Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 19: 151–156, 1996.PubMedGoogle Scholar
  67. 67.
    Ghazzi M, Radke-Mitchell L, Venable T, The troglitazone study group, Whitcomb R. Troglitazone improves glycemic control in patients with type ii diabetes who are not optimally controlled on sulfonylurea. Diabetes 46 (Suppl 1): 44A, 1997.Google Scholar
  68. 68.
    Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338: 867–72, 1998.PubMedGoogle Scholar
  69. 69.
    Schwartz S, Raskin P, Fonesca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338: 861–6, 1998.PubMedGoogle Scholar
  70. 70.
    Antonucci T, Whitcomb R, McLain R, Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 20: 188–193, 1997.PubMedGoogle Scholar
  71. 71.
    Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188–1193, 1994.PubMedGoogle Scholar
  72. .Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81: 3299–3306, 1996.Google Scholar
  73. 73.
    Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19: 217–31, 1998.PubMedGoogle Scholar
  74. 74.
    Buchanan TA, Xiang AH, Peters RK, et al. Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone. Program and abstracts of the 61st Scientific Sessions of the American Diabetes Association; June 22–26, 2001; Philadelphia, Pennsylvania. Diabetes 50(suppl 2):Abstract 327-PP, 2001.Google Scholar
  75. 75.
    Bailey CJ, Day C. Thiazolidinediones today. Br J Vasc Dis 1: 7–13, 2001.Google Scholar
  76. 76.
    Manson JE, Faich GA. Pharmacotherapy for obesity-do the benefits outweigh the risks? N Engl J Med 335: 659–660, 1996.PubMedGoogle Scholar
  77. 77.
    Albu J, Konnarides C, Pi-Sunyer FX. Weight control: metabolic and cardiovascular effects. Diabetes Reviews 3: 335–347, 1995.Google Scholar
  78. 78.
    Chow CC, Ko GT, Tsang LW, Yeung VT, Chan JC, Cockram CS. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. Diabetes Care 20: 1122–112, 1997.PubMedGoogle Scholar
  79. 79.
    Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581–588, 1997.PubMedGoogle Scholar
  80. 80.
    Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med 12: 416–418, 1995.PubMedGoogle Scholar
  81. 81.
    Gray DS, Fujioka K, Devine W, Bray GA A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int J Obes Relat Metab Disord 16(suppl)4: S67–S72, 1992.Google Scholar
  82. 82.
    Wise SD. Clinical studies with fluoxetine in obesity. Am J Clin Nutr 55 (suppl): 181S–184S, 1992.PubMedGoogle Scholar
  83. 83.
    Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain A, Kaise4r PE, Mendels J, Ryan D, Schwartz SL. Sibutramine dose response and long-term efficacy in weight loss. Int J Obes 18 (suppl 2): 60, 1994.Google Scholar
  84. 84.
    Manning RM, Jung RT, Lesse GP, Newton RW. The comparison of four weight reduction strategies aimed at overweight diabetic patients.Diabet Med 12: 409–415, 1995.Google Scholar
  85. 85.
    Hollander P. A 57-week study of orlistat in the treatment of obese patients with Type II diabetes. Diabetes 46 (Suppl 1): 54A, 1997.Google Scholar
  86. 86.
    Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjostrom L. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 32000; 160: 1321–6, 1997.Google Scholar
  87. 87.
    Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21:1288–94. 89, 1998.Google Scholar
  88. 88.
    Jacober SJ, Sowers JR. An update on perioperative management of diabetes. Arch Intern Med 159: 2405–11, 1999.PubMedGoogle Scholar
  89. 89.
    Golden SH, Peart-Vigilance C, Kao WH, Brancati FL.Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 22:1408–14, 1999Google Scholar
  90. 90.
    Pomposelli JJ, Baxter JK 3rd, Babineau TJ, Pomfret EA, Driscoll DF, Forse RA, Bistrian BR.Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. J Parenter Enteral Nutr 22: 77–81, 1998.Google Scholar
  91. 91.
    Hugo JM, Ockert DB. Routine peri-operative management of the diabetic patient. S Afr J Surg 30: 85–9, 1992.PubMedGoogle Scholar
  92. 92.
    Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A.Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 63: 356–61, 1997.PubMedGoogle Scholar
  93. 93.
    Peters A, Kerner W. Perioperative management of the diabetic patient. Exp Clin Endocrinol Diabetes 103: 213–8, 1995.PubMedGoogle Scholar
  94. 94.
    Eldridge AJ, Sear JW.Peri-operative management of diabetic patients. Any changes for the better since 1985? Anaesthesia 51: 45–51, 1996.PubMedGoogle Scholar
  95. 95.
    Simmons D, Morton K, Laughton SJ, Scott DJ.A comparison of two intravenous insulin regimens among surgical patients with insulin-dependent diabetes mellitus. Diabetes Educ 20: 422–7, 1994.PubMedGoogle Scholar
  96. 96.
    Raucoules-Aime M, Lugrin D, Boussofara M, Gastaud P, Dolisi C, Grimaud D. Intraoperative glycaemic control in non-insulin-dependent and insulin-dependent diabetes. Br J Anaesth 73: 443–9, 1994.PubMedGoogle Scholar
  97. 97.
    Hemmerling TM, Schmid MC, Schmidt J, Kern S, Jacobi KE.Comparison of a continuous glucose-insulin-potassium infusion versus intermittent bolus application of insulin on perioperative glucose control and hormone status in insulin-treated type 2 diabetics. J Clin Anesth 13: 293–300, 2001.PubMedGoogle Scholar
  98. 98.
    Hoogwerf BJ.Postoperative management of the diabetic patient. Med Clin North Am 85: 1213–28, 2001.Google Scholar
  99. 99.
    Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency. Diabetes Metab 22: 185–191, 1996.PubMedGoogle Scholar
  100. 100.
    Koivisto VA. Insulin therapy in type II diabetes. Diabetes Care 16 (Supp13): 29–39 102, 1993.Google Scholar
  101. 101.
    Wolffenbuttel BH, Weber RF, Weeks L, van Koetsveld PM, Verschoor L Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulfonylureas. Diabetes Res 13: 79–84, 1990.PubMedGoogle Scholar
  102. 102.
    Birkeland KI, Hanssen KF, Urdal P, Berg K, Vaaler S. A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. J Intern Med 236: 305–313, 1994.Google Scholar
  103. 103.
    Kudlacek S, Schernthaner G. The effect of insulin treatment on HbAlc, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. Horm Metab Res 24: 478–483, 1992.Google Scholar
  104. 104.
    Rosengren A, Adlerberth A, Bresater LE, Ehnberg S, Welin L. Multiple insulin injection therapy using an insulin pen-who benefits? A clinical 3-year follow-up study of 100 type 1 and 51 type 2 diabetic patients. Diabetes Res Clin Pract 20: 69–74, 1993.Google Scholar
  105. 105.
    Cull CA, Holman RR, Turner RC for the UK Prospective Diabetes Study (UKPDS) Group. Treatment of NIDDM-progressive requirement for polypharmacy to attain glycaemic goals. Diabetologia 40 (Suppl 1):Al-A722 (abstract 1366), 1997.Google Scholar
  106. 106.
    Mooradian AD. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs 51: 931–941, 1996.PubMedGoogle Scholar
  107. 107.
    Peters AL, Davidson MB Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 115: 45–53, 1991.PubMedGoogle Scholar
  108. 108.
    Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 156: 259–264, 1996.PubMedGoogle Scholar
  109. 109.
    Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes 44: 165–172, 1995.PubMedGoogle Scholar
  110. 108.
    Miller JL, Salman K, Shulman LH, Rose LI. Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes. Clin Pharmacol Ther 53: 380–384, 1993.PubMedGoogle Scholar
  111. 109.
    Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 18: 307–314, 1995.PubMedGoogle Scholar
  112. 110.
    Niskanen L, Lahti J, Uusitupa M. Morning or bed-time insulin with or without glibenclamide in elderly type 2 diabetic patients unresponsive to oral antidiabetic agents. Diabetes Res Clin Pract 18 (3): 185–190, 1992.PubMedGoogle Scholar
  113. 111.
    Clauson P, Karlander S, Steen L, Efendic S. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulfonylurea failure: a 1-year follow-up. Diabet Med 13: 471–477, 1996.PubMedGoogle Scholar
  114. 112.
    Landsted-Hallin L, Adamson U, Amer A, Bolinder J, Lins PE. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 18: 1183–1186, 1995.Google Scholar
  115. 113.
    Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 20: 1539–1542, 1997.PubMedGoogle Scholar
  116. 114.
    Riddle MC. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. HormMetab Res 28: 430433, 1996.Google Scholar
  117. 115.
    Klein W. Sulfonylurea-metformin-combination versus sulfonylureainsulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients. Diab Metab 17: 235–240, 1991.Google Scholar
  118. 116.
    Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy? Diab Metab 7: 218–223, 1991.Google Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Zachary Bloomgarden

There are no affiliations available

Personalised recommendations